These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33909922)

  • 1. Refractory primary autoimmune myelofibrosis treated with ruxolitinib.
    Otoukesh S; Song JY; Mojtahedzadeh M; Mokhtari S; Marcucci G; Pullarkat V; Ali H
    Am J Hematol; 2021 Aug; 96(8):E283-E285. PubMed ID: 33909922
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis.
    Barone M; Ricci F; Sollazzo D; Ottaviani E; Romano M; Auteri G; Bartoletti D; Reggiani MLB; Vianelli N; Tazzari PL; Cavo M; Forte D; Palandri F; Catani L
    Br J Haematol; 2019 Jun; 185(5):987-991. PubMed ID: 30450539
    [No Abstract]   [Full Text] [Related]  

  • 3. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
    Talpaz M; Erickson-Viitanen S; Hou K; Hamburg S; Baer MR
    J Hematol Oncol; 2018 Aug; 11(1):101. PubMed ID: 30086777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib (Jakafi) for myelofibrosis.
    Med Lett Drugs Ther; 2012 Apr; 54(1387):27-8. PubMed ID: 22469651
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib.
    Iurlo A; Cattaneo D; Boiocchi L; Orofino N; Fermo E; Cortelezzi A; Gianelli U
    Ann Hematol; 2015 Oct; 94(10):1749-51. PubMed ID: 26082334
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
    Passamonti F; Gupta V; Martino B; Foltz L; Zaritskey A; Al-Ali HK; Tavares R; Maffioli M; Raanani P; Giraldo P; Griesshammer M; Guglielmelli P; Bouard C; Paley C; Tiwari R; Vannucchi AM
    Hematol Oncol; 2021 Oct; 39(4):558-566. PubMed ID: 34224180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant-a pilot study.
    Pu JJ; Poulose J; Malysz J; Zhu J; Fanburg-Smith JC; Claxton DF; Bayerl MG
    Br J Haematol; 2019 Sep; 186(5):e130-e133. PubMed ID: 31115038
    [No Abstract]   [Full Text] [Related]  

  • 9. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
    Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
    Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis.
    Maccaferri M; Leonardi G; Marasca R; Colaci E; Paolini A; Soci F; Forghieri F; Potenza L; Narni F; Luppi M
    Leuk Lymphoma; 2014 Sep; 55(9):2207-8. PubMed ID: 24354678
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term outcome of treatment with ruxolitinib in myelofibrosis.
    Tefferi A; Litzow MR; Pardanani A
    N Engl J Med; 2011 Oct; 365(15):1455-7. PubMed ID: 21995409
    [No Abstract]   [Full Text] [Related]  

  • 12. [Ruxolitinib prescription in myelofibrosis].
    Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
    Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib for myelofibrosis therapy: current context, pros and cons.
    Pardanani A
    Leukemia; 2012 Jul; 26(7):1449-51. PubMed ID: 22285996
    [No Abstract]   [Full Text] [Related]  

  • 14. Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis.
    Caocci G; Maccioni A; Murgia F; Perra A; Usai M; Piga M; Mascia R; La Nasa G
    Leuk Lymphoma; 2016 May; 57(5):1215-8. PubMed ID: 26308187
    [No Abstract]   [Full Text] [Related]  

  • 15. Klebsiella pneumoniae primary liver abscess associated with ruxolitinib.
    Kusano Y; Terui Y; Ueda K; Hatake K
    Ann Hematol; 2016 Sep; 95(9):1561-2. PubMed ID: 27259987
    [No Abstract]   [Full Text] [Related]  

  • 16. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.
    Stübig T; Alchalby H; Ditschkowski M; Wolf D; Wulf G; Zabelina T; Wolschke C; Ayuk F; Kröger N
    Leukemia; 2014 Aug; 28(8):1736-8. PubMed ID: 24569777
    [No Abstract]   [Full Text] [Related]  

  • 17. Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.
    Bjørn ME; Holmström MO; Hasselbalch HC
    Leuk Lymphoma; 2016; 57(1):125-8. PubMed ID: 25936872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?
    Breccia M; Molica M; Colafigli G; Alimena G
    Expert Rev Hematol; 2015 Aug; 8(4):387-9. PubMed ID: 25915176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib.
    Mesa RA; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2012 Feb; 11(2):103-4. PubMed ID: 22293561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.